142 results on '"Jenny Lin"'
Search Results
2. Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature
- Author
-
Luiza Perez, Emily Webster, Leslie Bull, Jesse T. Brewer, Muhammad Danyal Ahsan, Jenny Lin, Sarah R. Levi, Evelyn Cantillo, Eloise Chapman-Davis, Kevin Holcomb, Shoshana M. Rosenberg, and Melissa K. Frey
- Subjects
Oncology ,Obstetrics and Gynecology - Published
- 2023
3. One‐click at a time: Empowering mothers for their adolescent children's educational expenditures through social media usage
- Author
-
Akshaya Vijayalakshmi and Meng‐Hsien (Jenny) Lin
- Subjects
Marketing ,Economics and Econometrics ,Public Health, Environmental and Occupational Health ,Applied Psychology - Published
- 2022
4. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis
- Author
-
Melissa K. Frey, Muhammad Danyal Ahsan, Hannah Bergeron, Jenny Lin, Xuan Li, Rana K. Fowlkes, Priyanka Narayan, Roni Nitecki, Jose Alejandro Rauh-Hain, Haley A. Moss, Becky Baltich Nelson, Charlene Thomas, Paul J. Christos, Jada G. Hamilton, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Allison W. Kurian, Steven Lipkin, Kenneth Offit, and Ravi N. Sharaf
- Subjects
Cancer Research ,Oncology ,Privacy ,Neoplastic Syndromes, Hereditary ,Humans ,Genetic Predisposition to Disease ,Genetic Counseling - Abstract
PURPOSE Evidence-based guidelines recommend cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for early detection and prevention of cancer. The current standard is for patients to contact and encourage relatives (patient-mediated contact) to undergo counseling and testing. Direct relative contact by the medical team or testing laboratory has shown promise but is complicated by privacy laws and lack of infrastructure. We sought to compare outcomes associated with patient-mediated and direct relative contact for hereditary cancer cascade genetic counseling and testing in the first meta-analysis on this topic. MATERIALS AND METHODS We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO No.: CRD42020134276). We searched key electronic databases to identify studies evaluating hereditary cancer cascade testing. Eligible trials were subjected to meta-analysis. RESULTS Eighty-seven studies met inclusion criteria. Among relatives included in the meta-analysis, 48% (95% CI, 38 to 58) underwent cascade genetic counseling and 41% (95% CI, 34 to 48) cascade genetic testing. Compared with the patient-mediated approach, direct relative contact resulted in significantly higher uptake of genetic counseling for all relatives (63% [95% CI, 49 to 75] v 35% [95% CI, 24 to 48]) and genetic testing for first-degree relatives (62% [95% CI, 49 to 73] v 40% [95% CI, 32 to 48]). Methods of direct contact included telephone calls, letters, and e-mails; respective rates of genetic testing completion were 61% (95% CI, 51 to 70), 48% (95% CI, 37 to 59), and 48% (95% CI, 45 to 50). CONCLUSION Most relatives at risk for hereditary cancer do not undergo cascade genetic counseling and testing, forgoing potentially life-saving medical interventions. Compared with patient-mediated contact, direct relative contact increased rates of cascade genetic counseling and testing, arguing for a shift in the care delivery paradigm, to be confirmed by randomized controlled trials.
- Published
- 2022
5. Neuromarketing as a scale validation tool: Understanding individual differences based on the style of processing scale in affective judgements
- Author
-
Meng‐Hsien (Jenny) Lin, William Jones, and Terry L. Childers
- Subjects
Social Psychology ,Applied Psychology - Published
- 2023
6. Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis
- Author
-
Muhammad Danyal Ahsan, Sarah R. Levi, Emily M. Webster, Hannah Bergeron, Jenny Lin, Priyanka Narayan, Becky Baltich Nelson, Xuan Li, Rana K. Fowlkes, Jesse T. Brewer, Charlene Thomas, Paul J. Christos, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Ravi N. Sharaf, and Melissa K. Frey
- Published
- 2023
7. Data from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
- Author
-
Jianjun Zhao, Jianhong Lin, Nikhil C. Munshi, Leal C. Herlitz, Kenneth C. Anderson, Thomas LaFramboise, Shan Yan, Jennifer S. Yu, Qing Y. Zheng, Xin Qi, Jack Khouri, Faiz Anwer, Alex Mejia-Garcia, Xiaofeng Jiang, Yusaku Nakabeppu, Daisuke Tsuchimoto, Allison J. Janocha, Mei Yin, Hua Fang, Ariel Kwart, Li Xue, Chuanfeng Fang, Chen Li, Jenny Lin, Mohsin Maqbool, Tania Amorim, Chun Yang, and Yi Hu
- Abstract
Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal tubule cells (PTC) following cisplatin-induced nuclear DNA and mitochondrial DNA damage in cisplatin-treated C57B6J mice. The APE2 transgenic mouse phenotype recapitulated the pathophysiological features of C-AKI (acute kidney injury, AKI) in the absence of cisplatin treatment. APE2 pulldown-MS analysis revealed that APE2 binds myosin heavy-Chain 9 (MYH9) protein in mitochondria after cisplatin treatment. Human MYH9-related disorder is caused by mutations in MYH9 that eventually lead to nephritis, macrothrombocytopenia, and deafness, a constellation of symptoms similar to the toxicity profile of cisplatin. Moreover, cisplatin-induced C-AKI was attenuated in APE2-knockout mice. Taken together, these findings suggest that cisplatin promotes AKI development by upregulating APE2, which leads to subsequent MYH9 dysfunction in PTC mitochondria due to an unrelated role of APE2 in DNA damage repair. This postulated mechanism and the availability of an engineered transgenic mouse model based on the mechanism of C-AKI provides an opportunity to identify novel targets for prophylactic treatment of this serious disease.Significance:These results reveal and highlight an unexpected role of APE2 via its interaction with MYH9 and suggest that APE2 has the potential to prevent acute kidney injury in patients with cisplatin-treated cancer.
- Published
- 2023
8. Supplementary Data from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
- Author
-
Jianjun Zhao, Jianhong Lin, Nikhil C. Munshi, Leal C. Herlitz, Kenneth C. Anderson, Thomas LaFramboise, Shan Yan, Jennifer S. Yu, Qing Y. Zheng, Xin Qi, Jack Khouri, Faiz Anwer, Alex Mejia-Garcia, Xiaofeng Jiang, Yusaku Nakabeppu, Daisuke Tsuchimoto, Allison J. Janocha, Mei Yin, Hua Fang, Ariel Kwart, Li Xue, Chuanfeng Fang, Chen Li, Jenny Lin, Mohsin Maqbool, Tania Amorim, Chun Yang, and Yi Hu
- Abstract
Table S1: MS/MS analyses of APE2 pull-down proteins in 293T cells
- Published
- 2023
9. Fig S2 from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
- Author
-
Jianjun Zhao, Jianhong Lin, Nikhil C. Munshi, Leal C. Herlitz, Kenneth C. Anderson, Thomas LaFramboise, Shan Yan, Jennifer S. Yu, Qing Y. Zheng, Xin Qi, Jack Khouri, Faiz Anwer, Alex Mejia-Garcia, Xiaofeng Jiang, Yusaku Nakabeppu, Daisuke Tsuchimoto, Allison J. Janocha, Mei Yin, Hua Fang, Ariel Kwart, Li Xue, Chuanfeng Fang, Chen Li, Jenny Lin, Mohsin Maqbool, Tania Amorim, Chun Yang, and Yi Hu
- Abstract
Normal morphology in other organs.
- Published
- 2023
10. Fig S1 from Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
- Author
-
Jianjun Zhao, Jianhong Lin, Nikhil C. Munshi, Leal C. Herlitz, Kenneth C. Anderson, Thomas LaFramboise, Shan Yan, Jennifer S. Yu, Qing Y. Zheng, Xin Qi, Jack Khouri, Faiz Anwer, Alex Mejia-Garcia, Xiaofeng Jiang, Yusaku Nakabeppu, Daisuke Tsuchimoto, Allison J. Janocha, Mei Yin, Hua Fang, Ariel Kwart, Li Xue, Chuanfeng Fang, Chen Li, Jenny Lin, Mohsin Maqbool, Tania Amorim, Chun Yang, and Yi Hu
- Abstract
Slight increase of APE2 expression in mouse PTCs after carboplatin and oxaliplatin treatment.
- Published
- 2023
11. Poetics of Cross-Cultural Relation: Critical Performances by Artists kate-hers RHEE and Patty Chang
- Author
-
Jenny Lin
- Abstract
This article explores anti-racist, feminist performance and video art by kate-hers RHEE and Patty Chang. Parodic performances of awkward sexual encounters in works such as RHEE’s The Chocolate Kiss (2013) and Chang’s The Product Love (2009) embody and deconstruct identity formation within transnational German and Asian American contexts. I explore how RHEE and Chang distinctly challenge sexist and racist stereotypes and the objectification of Asian women, while problematizing cultural categorization through (mis)translations and poetic relations. The article illuminates how these artists complicate Asian American identities via variegated explorations of critical race theories and connected histories of cross-cultural representation.
- Published
- 2022
12. Special Session: Creating Synergies from Multi-Method Research Approach: An Abstract
- Author
-
Meng-Hsien Jenny Lin, Samantha N. N. Cross, Akon E. Ekpo, Karla Corres Luna, and Akshaya Vijayalakshmi
- Published
- 2023
13. Animals in Our Lives
- Author
-
Hilary Downey, Meng-Hsien (Jenny) Lin, Nancy V. Wünderlich, Karen Kraus, Michael B. Beverland, Henna Syrjälä, and Jill Mosteller
- Subjects
Marketing ,Quality of life ,Resilience ,05 social sciences ,Perspective (graphical) ,Well-being ,Loneliness ,animals ,animal welfare, quality of life, well-being, resilience ,Quality of life (healthcare) ,Animal wewlfare ,Animal welfare ,0502 economics and business ,medicine ,Animals ,050211 marketing ,0501 psychology and cognitive sciences ,050102 behavioral science & comparative psychology ,medicine.symptom ,Psychology ,Resilience (network) ,Social psychology - Abstract
Humans have long interacted with animals. Recently, market-based responses to societal challenges, including loneliness and mental well-being include the use of animals. Considerable research concerning consumer–animal relationships has also examined the benefits (micro, meso, and macro) of human-animal interaction and companionship. However, much of this research is fragmented and lacks a broader organizing framework. It also suffers from an anthropomorphic bias, whereby the interests of animals are excluded. To address this, we provide a macromarketing perspective on consumer–animal relations and explore the interdependencies of consumer–animal relationships on consumer, animal, and community well-being. We introduce and apply the Interactive Well-Being framework to four contexts –ranging from private to public consumption spaces– that highlight the interdependencies and systems involved in consumer–animal relationships: (1) co-habitation with animals, (2) emotional support animals, (3) working with animals, and (4) animals in commercial service contexts. We discuss the implications of our framework for the resilience of marketing systems and how the framework aligns with alternative economy development.
- Published
- 2021
14. EP272/#1143 Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: a systematic review and meta-analysis
- Author
-
Priyanka Narayan, Muhammed Ahsan, Shanice Beaumont, Jenny Lin, Luiza Perez, Leslie Bull, Isabel Wolfe, Andy Hickner, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Ravi Sharaf, and Melissa Frey
- Published
- 2022
15. Calcitonin Gene-Related Peptide Receptor Positive Neurons In Central Amygdala Modulate Pain In Mice
- Author
-
Sudhuman Singh, Torri D. Wilson, Spring Valdivia, Jenny Lin, Ana Danko, and Yarimar Carrasquillo
- Subjects
Anesthesiology and Pain Medicine ,Neurology ,Neurology (clinical) - Published
- 2023
16. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis
- Author
-
Stephanie V. Blank, Ravi Sharaf, Steven M. Lipkin, Julia Feit, Paul J. Christos, Jenny Lin, Kevin Holcomb, Kenneth Offit, Charlene Thomas, Drew Wright, Hannah Bergeron, Danyal Ahsan, Melissa K. Frey, Rachel Saganty, Evelyn Cantillo, Andrea Khoury, Eloise Chapman-Davis, and Ying Liu
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Telemedicine ,Referral ,Genetic counseling ,DNA Mutational Analysis ,Psychological intervention ,Genetic Counseling ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Intervention (counseling) ,medicine ,Humans ,Genetic Testing ,Referral and Consultation ,Early Detection of Cancer ,Genetic testing ,BRCA2 Protein ,Ovarian Neoplasms ,medicine.diagnostic_test ,BRCA1 Protein ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Meta-analysis ,Female ,business ,Ovarian cancer - Abstract
Purpose Several professional organizations recommend universal genetic assessment for people with ovarian cancer as identifying pathogenic variants can affect treatment, prognosis, and all-cause mortality for patients and relatives. We sought to evaluate the literature on genetic assessment for women with ovarian cancer and determine if any interventions or patient characteristics drive utilization of services. Methods We searched key electronic databases to identify trials that evaluated genetic assessment for people with ovarian cancer. Trials with the primary aim to evaluate utilization of genetic assessment with or without interventions were included. Eligible trials were subjected to meta-analysis and the moderating influence of health interventions on rates of genetic assessment were examined. Results A total of 35 studies were included (19 report on utilization of genetic services without an intervention, 7 with an intervention, and 9 with both scenarios). Without an intervention, pooled estimates for referral to genetic counseling and completion of genetic testing were 39% [CI 27–53%] and 30% [CI 19–44%]. Clinician-facilitated interventions included: mainstreaming of genetic services (99% [CI 86–100%]), telemedicine (75% [CI 43–93%]), clinic-embedded genetic counselor (76% [CI 32–95%]), reflex tumor somatic genetic assessment (64% [CI 17–94%]), universal testing (57% [28–82%]), and referral forms (26% [CI 10–53%]). Random-effects pooled proportions demonstrated that Black vs. White race was associated with a lower rate of genetic testing (26%[CI 17–38%] vs. 40% [CI 25–57%]) as was being un-insured vs. insured (23% [CI 18–28%] vs. 38% [CI 26–53%]). Conclusions Reported rates of genetic testing for people with ovarian cancer remain well below the goal of universal testing. Interventions such as mainstreaming can improve testing uptake. Strategies aimed at improving utilization of genetic services should consider existing disparities in race and insurance status.
- Published
- 2021
17. β1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations
- Author
-
Sara McCurdy, Jenny Lin, Robert Shenkar, Thomas Moore, Rhonda Lightle, Eva Faurobert, Miguel‐Alejandro Lopez‐Ramirez, Issam Awad, Mark H. Ginsberg, University of California [San Diego] (UC San Diego), University of California (UC), University of Chicago, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), and Faurobert, Eva
- Subjects
Hemangioma, Cavernous, Central Nervous System ,Integrins ,endothelium ,[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,Integrin beta1 ,[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology ,Antibodies, Monoclonal ,[SDV.BDD.MOR]Life Sciences [q-bio]/Development Biology/Morphogenesis ,cerebral cavernous malformation ,Biochemistry ,[SDV.BDD.MOR] Life Sciences [q-bio]/Development Biology/Morphogenesis ,Mice ,β1 integrin ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Genetics ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Human Umbilical Vein Endothelial Cells ,Animals ,Humans ,Molecular Biology ,Microtubule-Associated Proteins ,Biotechnology - Abstract
International audience; β1 integrins are important in blood vessel formation and function, finely tuning the adhesion of endothelial cells to each other and to the extracellular matrix. The role of integrins in the vascular disease, cerebral cavernous malformation (CCM) has yet to be explored in vivo. Endothelial loss of the gene KRIT1 leads to brain microvascular defects, resulting in debilitating and often fatal consequences. We tested administration of a monoclonal antibody that enforces the active β1 integrin conformation, (clone 9EG7), on a murine neonatal CCM mouse model, Krit1 flox/flox ;Pdgfb-iCreERT2 (Krit1 ECKO), and on KRIT1-silenced human umbilical vein endothelial cells (HUVECs). In addition, endothelial deletion of the master regulator of integrin activation, Talin 1 (Tln1), in Krit1 ECKO mice was performed to assess the effect of completely blocking endothelial integrin activation on CCM. Treatment with 9EG7 reduced lesion burden in the Krit1 ECKO model and was accompanied by a strong reduction in the phosphorylation of the ROCK substrate, myosin light chain (pMLC), in both retina and brain endothelial cells. Treatment of KRIT1-silenced HUVECs with 9EG7 in vitro stabilized cell-cell junctions. Overnight treatment of HUVECs with 9EG7 resulted in significantly reduced total surface expression of β1 integrin, which was associated with reduced pMLC levels, supporting our in vivo findings. Genetic blockade of integrin activation by Tln1 ECKO enhanced bleeding and did not reduce CCM lesion burden in Krit1 ECKO mice. In sum, targeting β1 integrin with an activated-specific antibody reduces acute murine CCM lesion development, which we found to be associated with suppression of endothelial ROCK activity.
- Published
- 2022
18. PSAT231 Perceived Cognitive Function Is Associated With Adherence to Diabetes Self-Management Behaviors Among Breast Cancer Survivors
- Author
-
Jennifer Itty, Sherene Lambert, Thomas Annesi, Courtney Chan, Mita Goel, Jenny Lin, and Yael Harris
- Subjects
Endocrinology, Diabetes and Metabolism - Abstract
Introduction In the United States, the annual incidence of breast cancer and comorbid type 2 diabetes mellitus (T2DM) in women is ∼40,000. Both conditions are associated with cognitive decline, which adversely affects self-management behaviors (SMBs) including adherence to medication, dietary and exercise recommendations. Patients with breast cancer also self-report decreased cognitive ability. Such perceptions can result from objective decline in cognitive function as well as factors such as anxiety and depression. Yet, the effect of perceived cognitive function on diabetes SMBs remains unclear. We evaluated the relationship between perceived cognitive function and adherence to SMBs in breast cancer survivors with T2DM. Hypothesis Greater adherence to diabetes SMBs will be associated with higher perceived cognitive function. Methodology We enrolled women ≥ 55 years with pre-existing T2DM who were diagnosed with Stage 0-IIIA breast cancer in the past 15 years, had completed adjuvant chemotherapy and/or prescribed hormonal therapy, and were taking ≥ 1 oral diabetes medication. We measured perceived cognitive function with the Functional Assessment of Cancer Therapy-Cognition (FACT-Cog, version 3) and diabetes SMBs adherence with the Summary of Diabetes Self Care Activities (SDSCA) questionnaire. Adherence to diabetes medications was assessed using an electronic monitoring bottlecap (eCAP). Data were dichotomized into adherent vs non-adherent. Wilcoxon rank-sum tests were used to compare cognition scores between groups. Results 239 patients (mean age: 66.5 years; 28% Black, 39% white, 6% Asian, 7% other, 20% unanswered) completed interviews. Cancer survivors who were non-adherent with their diabetes medication perceived themselves as having lower cognitive function (Total FACT-Cog median (interquartile range; IQR) 102 (36.7) vs. 115 (30), p< 0.05), with lower scores on the perceived cognitive ability and impact of cognitive impairments on quality of life (QOL) subscales (Cognitive-ability median (IQR) 20 (9) vs. 23 (7), p< 0.001; QOL median (IQR) 13 (6) vs 16 (3), p< 0.05). Similarly, those who reported healthy eating for Conclusion Among breast cancer survivors with T2DM, adherence to diet and medication was associated with greater self-perceptions of cognitive function. Future studies will test whether interventions to improve patients’ perceptions of their cognitive abilities can influence self-care. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m., Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m.
- Published
- 2022
19. Recommendations on qPCR/ddPCR assay validation by GCC
- Author
-
Mark Wissel, Martin Poirier, Christina Satterwhite, John Lin, Rafiq Islam, Jennifer Zimmer, Ardeshir Khadang, Jennifer Zemo, Todd Lester, Marianne Fjording, Amanda Hays, Nicola Hughes, Fabio Garofolo, Rudolf Guilbaud, Elizabeth Groeber, Heidi Renfrew, Kelly Colletti, Mathilde Yu, Jenny Lin, Xinping Fang, Santosh Shah, Wei Garofolo, Sumit Kar, Roger Hayes, John Pirro, Cheikh Kane, Marsha Luna, Allan Xu, Stephanie Cape, Mark O'Dell, Robert Wheller, Hanna Ritzen, Jennifer Vance, Esme Farley, Katie Matys, Edward Tabler, William Mylott, Moucun Yuan, Shane Karnik, Troy Voelker, Ira DuBey, Clark Williard, Jing Shi, and Jim Yamashita
- Subjects
Medical Laboratory Technology ,Clinical Biochemistry ,Biological Assay ,General Medicine ,General Pharmacology, Toxicology and Pharmaceutics ,Real-Time Polymerase Chain Reaction ,Analytical Chemistry - Abstract
Gene therapy, cell therapy and vaccine research have led to an increased use of qPCR/ddPCR in bioanalytical laboratories. CROs are progressively undertaking the development and validation of qPCR and ddPCR assays. Currently, however, there is limited regulatory guidance for the use of qPCR and a complete lack of any regulatory guidelines for the use of the newer ddPCR to support regulated bioanalysis. Hence, the Global CRO Council in Bioanalysis (GCC) has issued this White Paper to provide; 1) a consensus on the different validation parameters required to support qPCR/ddPCR assays; 2) a harmonized approach to their validation and 3) a consistent development of standard operating procedures (SOPs) for all the bioanalytical laboratories using these techniques.
- Published
- 2022
20. Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury
- Author
-
Nikhil C. Munshi, Daisuke Tsuchimoto, Mei Yin, Allison J. Janocha, Yi Hu, Hua Fang, Shan Yan, Thomas LaFramboise, Li Xue, Alex Mejia-Garcia, Chen Li, Chun Yang, Jennifer S. Yu, Jianhong Lin, Kenneth C. Anderson, Chuanfeng Fang, Yusaku Nakabeppu, Qing Y. Zheng, Tania Amorim, Xin Qi, Leal Herlitz, Faiz Anwer, Jenny Lin, Jack Khouri, Mohsin Maqbool, Ariel Kwart, Xiaofeng Jiang, and Jianjun Zhao
- Subjects
0301 basic medicine ,Genetically modified mouse ,Cancer Research ,Mitochondrial Diseases ,DNA damage ,Hearing Loss, Sensorineural ,Transgene ,Antineoplastic Agents ,Mice, Transgenic ,Mitochondrion ,medicine.disease_cause ,DNA, Mitochondrial ,Article ,Carboplatin ,Kidney Tubules, Proximal ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,DNA-(Apurinic or Apyrimidinic Site) Lyase ,Animals ,Humans ,Medicine ,Mice, Knockout ,Cisplatin ,Mutation ,Nephritis ,Myosin Heavy Chains ,business.industry ,Acute kidney injury ,Acute Kidney Injury ,Endonucleases ,medicine.disease ,Multifunctional Enzymes ,Thrombocytopenia ,Mitochondria ,Up-Regulation ,Mice, Inbred C57BL ,Oxaliplatin ,Phenotype ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,business ,DNA Damage ,medicine.drug - Abstract
Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal tubule cells (PTC) following cisplatin-induced nuclear DNA and mitochondrial DNA damage in cisplatin-treated C57B6J mice. The APE2 transgenic mouse phenotype recapitulated the pathophysiological features of C-AKI (acute kidney injury, AKI) in the absence of cisplatin treatment. APE2 pulldown-MS analysis revealed that APE2 binds myosin heavy-Chain 9 (MYH9) protein in mitochondria after cisplatin treatment. Human MYH9-related disorder is caused by mutations in MYH9 that eventually lead to nephritis, macrothrombocytopenia, and deafness, a constellation of symptoms similar to the toxicity profile of cisplatin. Moreover, cisplatin-induced C-AKI was attenuated in APE2-knockout mice. Taken together, these findings suggest that cisplatin promotes AKI development by upregulating APE2, which leads to subsequent MYH9 dysfunction in PTC mitochondria due to an unrelated role of APE2 in DNA damage repair. This postulated mechanism and the availability of an engineered transgenic mouse model based on the mechanism of C-AKI provides an opportunity to identify novel targets for prophylactic treatment of this serious disease. Significance: These results reveal and highlight an unexpected role of APE2 via its interaction with MYH9 and suggest that APE2 has the potential to prevent acute kidney injury in patients with cisplatin-treated cancer.
- Published
- 2021
21. Chronic canaliculitis with canaliculoliths due to Providencia stuartii infection
- Author
-
Christopher E. Starr, Kyle J. Godfrey, Jenny Lin, and Victoria S. North
- Subjects
biology ,business.industry ,Streptococcus ,Providencia stuartii ,fungi ,food and beverages ,biology.organism_classification ,medicine.disease_cause ,digestive system ,Microbiology ,Ophthalmology ,Antibiotic resistance ,medicine.anatomical_structure ,Lacrimal canaliculi ,Canaliculitis ,Medicine ,business ,Staphylococcus ,Actinomyces ,Bacteria - Abstract
Canaliculitis, inflammation of the lacrimal canaliculi, can be caused by numerous pathogens, most commonly bacteria from the genera Actinomyces, Streptococcus, and Staphylococcus. Primary canalicul...
- Published
- 2021
22. Replication in Human Intestinal Enteroids of Infectious Norovirus from Vomit Samples
- Author
-
Lena Serrander, Tina Falkeborn, Johan Nordgren, Marie Hagbom, Sumit Sharma, Jan Albert, and Jenny Lin
- Subjects
Microbiology (medical) ,Infectious Medicine ,Norovirus RNA ,Projectile vomiting ,Epidemiology ,viruses ,norovirus ,Infektionsmedicin ,Infectious and parasitic diseases ,RC109-216 ,Biology ,medicine.disease_cause ,fluids and secretions ,medicine ,Humans ,Caliciviridae Infections ,Infectivity ,Sweden ,infectivity ,enteric infections ,Dispatch ,virus diseases ,biology.organism_classification ,Virology ,digestive system diseases ,Replication in Human Intestinal Enteroids of Infectious Norovirus from Vomit Samples ,Intestines ,Norwalk virus ,Infectious Diseases ,Norovirus ,vomit ,Medicine ,human intestinal enteroids - Abstract
A typical clinical symptom of human norovirus infection is projectile vomiting. Although norovirus RNA and viral particles have been detected in vomitus, infectivity has not yet been reported. We detected replication-competent norovirus in 25% of vomit samples with a 13-fold to 714-fold increase in genomic equivalents, confirming infectious norovirus. Funding Agencies|Swedish Research CouncilSwedish Research CouncilEuropean Commission [3R 2017-01479]; ALF Grants, Region Ostergotland [LIO-934451]
- Published
- 2021
23. A Presentation of Pediatric Sjögren's Syndrome with Abducens Nerve Palsy
- Author
-
Jenny Lin, Grace Y. Gombolay, Elaine R. Flanagan, and Judith A. Gadde
- Subjects
medicine.medical_specialty ,Adolescent ,Neurological disorder ,Myelitis, Transverse ,Transverse myelitis ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Optic neuritis ,Child ,Abducens nerve ,030203 arthritis & rheumatology ,business.industry ,Peripheral Nervous System Diseases ,General Medicine ,Middle Aged ,Abducens palsy ,medicine.disease ,Dermatology ,Cranial Nerve Diseases ,Sjogren's Syndrome ,Pediatrics, Perinatology and Child Health ,Acute disseminated encephalomyelitis ,Female ,Rituximab ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Abducens Nerve Diseases ,Parotitis ,medicine.drug - Abstract
Sjögren's syndrome is a systemic autoimmune disease that classically presents with xerophthalmia and xerostomia. However, neurological manifestations occur in 10 to 60% of patients with Sjögren's syndrome and can often precede classic sicca symptoms in Sjögren's syndrome in some cases up to several years. Rarely, cranial neuropathy can be the initial presentation. Here, we present the first case of a 15-year-old girl with left abducens palsy in the setting of a new diagnosis of Sjögren's syndrome. Comprehensive evaluation revealed elevated Sjögren's syndrome–related antigen A-60 antibody. Cerebrospinal fluid analysis was unremarkable. Radiological studies demonstrated evidence of chronic parotitis. Acute treatment included high-dose methylprednisolone and rituximab, and symptoms resolved by follow-up at 2 weeks. The most common neurological disorder of Sjögren's syndrome is pure sensory neuropathy. In pediatric Sjögren's syndrome, neurological complications are rare but include aseptic meningoencephalitis, acute disseminated encephalomyelitis, transverse myelitis, optic neuritis, and cranial neuropathies. In the circumstance of a cranial neuropathy, the trigeminal nerve is most commonly involved but oculomotor nerves can occasionally be affected. Abducens palsies have been described in four patients with Sjögren's syndrome, typically women and all middle aged or older, with our patient being the first pediatric case. Thus, it is important to consider screening for Sjögren's syndrome in the evaluation of pediatric patients with new onset of isolated cranial neuropathy even in the absence of classic sicca symptoms.
- Published
- 2020
24. Recommendations on ELISpot assay validation by the GCC
- Author
-
Rafiq Islam, Jennifer Vance, Martin Poirier, Jennifer Zimmer, Ardeshir Khadang, Dave Williams, Jennifer Zemo, Todd Lester, Marianne Fjording, Amanda Hays, Nicola Hughes, Fabio Garofolo, Curtis Sheldon, Rudolf Guilbaud, Christina Satterwhite, Kelly Colletti, Elizabeth Groeber, Heidi Renfrew, Mathilde Yu, Jenny Lin, Xinping Fang, Mark Wissel, Thomas Beadnell, John Lin, Santosh Shah, Wei Garofolo, Natasha Savoie, Roger Hayes, John Pirro, Cheikh Kane, Marsha Luna, Allan Xu, Stephanie Cape, Mark O'Dell, Robert Wheller, Hanna Ritzen, Esme Farley, Lisa Kierstead, William Mylott, Edward Tabler, Moucun Yuan, Shane Karnik, Troy Voelker, Ira DuBey, Clark Williard, Kelly Dong, Jing Shi, and Jim Yamashita
- Subjects
Medical Laboratory Technology ,Enzyme-Linked Immunospot Assay ,Clinical Biochemistry ,Cell- and Tissue-Based Therapy ,Humans ,Biological Assay ,General Medicine ,Genetic Therapy ,General Pharmacology, Toxicology and Pharmaceutics ,Analytical Chemistry - Abstract
Gene therapy, cell therapy and vaccine research have led to an increased need to perform cellular immunity testing in a regulated environment to ensure the safety and efficacy of these treatments. The most common method for the measurement of cellular immunity has been Enzyme-Linked Immunospot assays. However, there is a lack of regulatory guidance available discussing the recommendations for developing and validating these types of assays. Hence, the Global CRO Council has issued this white paper to provide a consensus on the different validation parameters required to support Enzyme-Linked Immunospot assays and a harmonized and consistent approach to Enzyme-Linked Immunospot validation among contract research organizations.
- Published
- 2022
25. Talin-1 is the principal platelet Rap1 effector of integrin activation
- Author
-
Miguel Alejandro Lopez-Ramirez, David S. Paul, Mark H. Ginsberg, Monica N. Cuevas, Hao Sun, Jenny Lin, Andrew J. Valadez, Wolfgang Bergmeier, Frederic Lagarrigue, Jailal N. G. Ablack, Alexandre R. Gingras, Department of Medicine, University of California, San Diego, La Jolla, CA, Institut de pharmacologie et de biologie structurale (IPBS), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées
- Subjects
0301 basic medicine ,Male ,Talin ,endocrine system ,animal structures ,Platelet Aggregation ,[SDV]Life Sciences [q-bio] ,Immunology ,Integrin ,macromolecular substances ,GTPase ,Biochemistry ,Thrombopoiesis ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Protein Domains ,Animals ,Point Mutation ,Platelet ,Platelet activation ,Mice, Knockout ,biology ,Chemistry ,Effector ,Integrin beta1 ,Integrin beta3 ,rap1 GTP-Binding Proteins ,Cell Biology ,Hematology ,Phosphatidylserine ,Platelet Activation ,Platelets and Thrombopoiesis ,Cell biology ,Mice, Inbred C57BL ,enzymes and coenzymes (carbohydrates) ,030104 developmental biology ,rap GTP-Binding Proteins ,030220 oncology & carcinogenesis ,Hemostasis ,embryonic structures ,biology.protein ,Female ,Rap1 ,Signal transduction ,Signal Transduction - Abstract
Ras-related protein 1 (Rap1) is a major convergence point of the platelet-signaling pathways that result in talin-1 binding to the integrin β cytoplasmic domain and consequent integrin activation, platelet aggregation, and effective hemostasis. The nature of the connection between Rap1 and talin-1 in integrin activation is an important remaining gap in our understanding of this process. Previous work identified a low-affinity Rap1-binding site in the talin-1 F0 domain that makes a small contribution to integrin activation in platelets. We recently identified an additional Rap1-binding site in the talin-1 F1 domain that makes a greater contribution than F0 in model systems. Here we generated mice bearing point mutations, which block Rap1 binding without affecting talin-1 expression, in either the talin-1 F1 domain (R118E) alone, which were viable, or in both the F0 and F1 domains (R35E,R118E), which were embryonic lethal. Loss of the Rap1–talin-1 F1 interaction in platelets markedly decreases talin-1–mediated activation of platelet β1- and β3-integrins. Integrin activation and platelet aggregation in mice whose platelets express only talin-1(R35E, R118E) are even more impaired, resembling the defect seen in platelets lacking both Rap1a and Rap1b. Although Rap1 is important in thrombopoiesis, platelet secretion, and surface exposure of phosphatidylserine, loss of the Rap1–talin-1 interaction in talin-1(R35E, R118E) platelets had little effect on these processes. These findings show that talin-1 is the principal direct effector of Rap1 GTPases that regulates platelet integrin activation in hemostasis.
- Published
- 2020
26. Evaluating Adolescents’ Responses to Internet Ads: Role of Ad Skepticism, Internet Literacy, and Parental Mediation
- Author
-
Akshaya Vijayalakshmi, Meng-Hsien (Jenny) Lin, and Russell N. Laczniak
- Subjects
Marketing ,business.industry ,Communication ,media_common.quotation_subject ,Advertising ,Literacy ,ComputingMilieux_GENERAL ,ComputingMilieux_COMPUTERSANDEDUCATION ,The Internet ,Business and International Management ,Parental mediation ,business ,Psychology ,media_common ,Skepticism - Abstract
In this article, we first compare adolescents’ responses to two formats (easily recognizable versus not easily recognizable) Internet ads. We find that Internet literacy and ad skepticism are neces...
- Published
- 2020
27. Prompting Sustainable Consumption Choices: Exploring the Role of Construal Level Theory: An Abstract
- Author
-
Saray Garcia, Crystal Loke, Angeline Nariswari, and Jenny Lin
- Published
- 2022
28. Be Good or Do Good? A Construal Level Theory Perspective on Corporate Ambivalent Behaviors: An Abstract
- Author
-
Gagandeep Choongh, Erika Hernandez-Gonzalez, Karla Corres Luna, and Meng-Hsien Jenny Lin
- Published
- 2022
29. 3. Silicon Wafers and Office Park Dreams : Cross-Cultural Designs, Aesthetics, and Art in and around California’s Santa Clara Valley
- Author
-
Jenny Lin
- Published
- 2021
30. Predicting a Mother's Role in Investing in Children's Education
- Author
-
Akshaya Vijayalakshmi, Meng-Hsien (Jenny) Lin, and Sarah Ricks
- Published
- 2021
31. Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting
- Author
-
Jenny Lin, Isabel Wolfe, Muhammad Danyal Ahsan, Hannah Krinsky, Andreas I. Lackner, Joe Pelt, Karen Bolouvi, Charlotte Gamble, Charlene Thomas, Paul J. Christos, Evelyn Cantillo, Kevin Holcomb, Eloise Chapman-Davis, Ravi Sharaf, Steven M. Lipkin, Stephanie V. Blank, and Melissa K. Frey
- Subjects
Oncology ,Obstetrics and Gynecology - Abstract
The literature demonstrates that the quality of cancer family history (CFH) as currently collected in the outpatient setting is inadequate to assess disease risk. Prior to implementation of a web-based application for cancer family history collection, we aimed to review the quality of collected CFH in a gynecologic oncology outpatient clinic and determine contributing patient factors. Medical records were reviewed for 200 new patients presenting between 4/2019-7/2019. CFH was collected during the patient interview and evaluated for inclusion of eight elements based on standards set by the genetics community. Univariate and multivariable linear regression analyses were utilized to evaluate the effect of patient characteristics on the number of relatives included in the CFH. Among our cohort of 200 patients, CFH was documented for 185 patients (92.5%). On univariate analysis, patients with a family history of cancer and prior genetic testing had significantly greater median number of relatives included in the CFH. On multivariable analysis, patients with family members with cancer had significantly more relatives included. Our data are consistent with the literature, suggesting that the current collection methods may not adequately capture all measures of a high quality CFH. Patients reporting no family history of cancer and those without prior genetic testing were least likely to have CFH that included key quality elements and these patients might benefit from health information technology CFH collection tools.
- Published
- 2021
32. Electroencephalography characteristics to predict one-year outcomes in pediatric anti-NMDA receptor encephalitis
- Author
-
Sonam Bhalla, Kathryn Elkins, Jenny Lin, Laura S. Blackwell, Satyanarayana Gedela, Leah Loerinc, Ammar Kheder, Robyn Howarth, Grace Y. Gombolay, and Guojun Zhang
- Subjects
Male ,medicine.medical_specialty ,Multivariate analysis ,Adolescent ,Population ,Electroencephalography ,Single Center ,Receptors, N-Methyl-D-Aspartate ,Article ,Epilepsy ,Modified Rankin Scale ,Internal medicine ,medicine ,Humans ,education ,Child ,Retrospective Studies ,Anti-NMDA receptor encephalitis ,Anti-N-Methyl-D-Aspartate Receptor Encephalitis ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Infant ,medicine.disease ,Neurology ,Child, Preschool ,Female ,Neurology (clinical) ,Immunotherapy ,business ,Encephalitis - Abstract
Background Electrographic characteristics (extreme delta brush, posterior dominant rhythm and slow waves) may predict outcomes in anti-NMDA receptor encephalitis (NMDARE). However, whether changes in EEG sleep architecture predict outcomes are unknown. We examine electrophysiological characteristics including sleep architecture in a pediatric NMDARE population and correlate with outcomes at one year. Methods Retrospective chart and EEG review was performed in pediatric NMDARE patients at a single center. Patients with first EEGs available within 48 h of admission, prior to treatment, and one-year follow-up data were included. EEGs were independently reviewed by two epileptologists, and a third when disagreement occurred. Clinical outcomes included modified Rankin scale (mRS) at one year. Results Nine patients (6 females) (range 1.9–16.7 years) were included. Five of nine patients had loss of posterior dominant rhythm (PDR) and three of nine patients had absent sleep architecture. Loss of PDR correlated with a worse mRS score at one year (2.8 versus 0.5, p = 0.038). Loss of PDR and loss of sleep architecture was associated with increased inpatient rehabilitation stay and in higher number of immunotherapy treatments administered. In multivariate analysis, absence of sleep architecture (p = 0.028), absence of PDR (p = 0.041), and epileptiform discharges (p = 0.041) were predictors of mRS at one year. Conclusions Loss of normal PDR, absence of sleep architecture, and epileptiform discharges are associated with worse outcomes at one year which has not been reported before. EEG characteristics may help prognosticate in NMDARE. Larger studies are needed to confirm these findings.
- Published
- 2021
33. Chronic canaliculitis with canaliculoliths due to
- Author
-
Jenny, Lin, Victoria S, North, Christopher, Starr, and Kyle J, Godfrey
- Abstract
Canaliculitis, inflammation of the lacrimal canaliculi, can be caused by numerous pathogens, most commonly bacteria from the genera
- Published
- 2021
34. LOW ANTIMÜLLERIAN HORMONE LEVEL IS NOT ASSOCIATED WITH ANEUPLOIDY IN MISCARRIAGES FROM PREGNANCIES CONCEIVED WITH ASSISTED REPRODUCTIVE TECHNOLOGY
- Author
-
Jenny Lin, Phillip A. Romanski, Pietro Bortoletto, and Alexis P. Melnick
- Subjects
Reproductive Medicine ,Obstetrics and Gynecology - Published
- 2022
35. Cascade testing for hereditary cancer syndromes: Should we move towards direct relative contact? A systematic review and meta-analysis (384)
- Author
-
Muhammad Danyal Ahsan, Hannah Bergeron, Jenny Lin, Rana Fowlkes, Priyanka Narayan, Roni Nitecki, Jose Rauh-Hain, Haley Moss, Xuan Li, Charlene Thomas, Paul Christos, Julia Feit, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Steven Lipkin, Ravi Sharaf, and Melissa Frey
- Subjects
Oncology ,Obstetrics and Gynecology - Published
- 2022
36. Reply to Dr. Witjes regarding universal tumor genomic sequencing as a prescreen for germline genetic testing in patients diagnosed with ovarian cancer
- Author
-
Jenny Lin and Melissa K. Frey
- Subjects
Oncology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Genomic sequencing ,Obstetrics and Gynecology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Gynecology and obstetrics ,medicine.disease ,Germline ,Internal medicine ,Correspondence ,medicine ,RG1-991 ,In patient ,business ,Ovarian cancer ,RC254-282 ,Genetic testing - Published
- 2021
37. Proangiogenic Collagen-Binding Glycan Therapeutic Promotes Endothelial Cell Angiogenesis
- Author
-
Tima Dehghani, Jenny Lin, Alyssa Panitch, Tanaya Walimbe, Aijun Wang, and Alena Casella
- Subjects
Angiogenesis ,Growth factor ,medicine.medical_treatment ,0206 medical engineering ,Biomedical Engineering ,Endothelial Cells ,Neovascularization, Physiologic ,02 engineering and technology ,021001 nanoscience & nanotechnology ,020601 biomedical engineering ,Dermatan sulfate ,In vitro ,Cell biology ,Proinflammatory cytokine ,Biomaterials ,Endothelial stem cell ,chemistry.chemical_compound ,chemistry ,In vivo ,Polysaccharides ,medicine ,Collagen ,0210 nano-technology ,Wound healing ,Signal Transduction - Abstract
Stimulating angiogenesis during wound healing continues to present a significant clinical challenge, given the limitations of current strategies to maintain therapeutic doses of growth factors and endothelial cell efficacy. Incorporating a balance of specific cues to encourage endothelial cell engraftment and cytokines to facilitate angiogenesis is necessary for blood vessel growth in the proinflammatory wound environment. Here, we incorporate a previously designed peptide (LXW7) capable of binding to the αvβ3 integrin of endothelial cells with a dermatan sulfate glycosaminoglycan backbone grafted with collagen-binding peptides (SILY). By exploiting αvβ3 integrin-mediated VEGF signaling, we propose an alternative strategy to overcome shortcomings of traditional growth factor therapy while homing the peptide to the wound bed. In this study, we describe the synthesis and optimization of LXW7-DS-SILY (LDS) variants and evaluate their angiogenic potential in vitro and in vivo. LDS displayed binding to collagen and endothelial cells. In vitro, the LDS variant with six LXW7 peptides increased endothelial cell proliferation, migration, and tubule formation through increased VEGFR2 phosphorylation compared to nontreated controls. In an in vivo chick chorioallantoic membrane assay, LDS laden collagen hydrogels increased blood vessel formation by 43% in comparison to the organism matched blank hydrogels. Overall, these findings demonstrate the potential of a robust targeted glycan therapeutic for promoting angiogenesis during wound healing.
- Published
- 2021
38. Comparison of Breast Reconstruction Outcomes Using Oxychlorosene versus Triple Antibiotic Solution for Pocket Irrigation
- Author
-
Ravinder, Bamba, Phu C, Tran, Brian A, Mailey, Jenny, Lin, William, DeBrock, Steven, Dawson, Mithun, Sinha, Brett C, Hartman, Ivan, Hadad, Mary E, Lester, and Aladdin H, Hassanein
- Abstract
Breast pocket irrigation with antiseptic solutions is performed to reduce contamination with breast implants. The optimal antiseptic irrigation solution and the efficacy of individual practices are unclear. Oxychlorosene sodium is frequently used at our institution. Oxychlorosene is bactericidal with a mechanism of action of oxidation and hypochlorination. The purpose of our study was to compare the outcomes of oxychlorosene sodium irrigation with triple antibiotic solution (TAS) in implant-based breast reconstruction.All patients who underwent implant-based reconstruction after mastectomy were reviewed. The primary predictive variable was type of solution used for pocket irrigation (TAS or oxychlorosene). Outcome variables included surgical site infection, device removal, and wound complications.Between 2013 and 2018, 331 implant-based breast reconstructions were performed. Of these, 62% (n = 206) received oxychlorosene for surgical pocket irrigation (group I), and 38% (n = 125) received TAS (group II). Group I had an 11.7% (n = 24) 90-day surgical site infection rate, with 4.9% (n = 10) requiring oral antibiotics, 2.4% (n = 5) requiring intravenous antibiotics without device removal, and 4.4% (n = 9) requiring prosthetic removal. Group II had an 11.2% (n = 14) 90-day infection rate, with 5.6% (n = 7) requiring oral antibiotics, 2.4% (n = 3) requiring intravenous antibiotics without device removal, and 3.2% (n = 4) requiring removal (Oxychlorosene and TAS have similar surgical site infection rates in prosthetic breast reconstruction. Ease of preparation and cost make oxychlorosene a more favorable option for antibiotic irrigation in reconstructive breast surgery with prosthetic devices.
- Published
- 2021
39. An Artin Braid Group Representation of Knitting Machine State with Applications to Validation and Optimization of Fabrication Plans
- Author
-
Jenny Lin and James McCann
- Subjects
Sequence ,Loop (graph theory) ,Computer science ,Heuristic ,visual_art ,Braid group ,Benchmark (computing) ,visual_art.visual_art_medium ,Braid ,Yarn ,Representation (mathematics) ,Algorithm - Abstract
Industrial knitting machines create fabric by manipulating loops held on hundreds of needles. A core problem in pattern making for these machines is transfer planning – coming up with a sequence of low-level operations that move loops to the appropriate needles so that knitting through those loops produces the correct final structure. Since each loop is connected to the larger piece in progress, transfer plans must account for not only loop position, but the way strands of yarn tangle around each other.We present the first complete, discrete representation of the machine’s loop-tangling process. Our representation combines a braid from the Artin Braid Group with an array of explicit loop positions to fully capture loop crossings. By storing braids in the Symmetric Normal Form, states can be quickly compared and updated incrementally with machine operations. This representation can be used to verify the equivalence of transfer operations, providing an important tool in optimizing knit manufacturing.We improve on prior work in transfer planning algorithms, which can only solve certain subclasses of problems and are frequently suboptimal in terms of fabrication time, by introducing a novel A* search heuristic and state-collapsing mechanism, which we show finds optimal transfer plans for a large benchmark set of small transfer planning problems.
- Published
- 2021
40. Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis
- Author
-
Priyanka Narayan, Muhammad Danyal Ahsan, Shanice Beaumont, Jenny Lin, Luiza Perez, Leslie Bull, Isabel Wolfe, Andy Hickner, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Ravi Sharaf, and Melissa Kristen Frey
- Subjects
Cancer Research ,Oncology - Abstract
e17597 Background: Approximately 20% of ovarian cancers are due to an underlying germline pathogenic variant. While several genes have been well-established in the development of hereditary ovarian cancer (e.g. BRCA1/2, RAD51C, RAD51D, BRIP1, mismatch repair genes), there are other genes for which the cancer risk is less certain and management recommendations remain controversial, including partner and localizer of BRCA 2 (PALB2). We sought to evaluate the association between PALB2 germline pathogenic mutations and ovarian cancer in the first meta-analysis on this topic. Methods: We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO no.: CRD42021281325). We searched key electronic databases to identify studies evaluating multigene panel testing in patients with ovarian cancer. Eligible trials were subjected to meta-analysis. Results: Thirty-seven studies met inclusion criteria. We found 55,137 cases of ovarian cancer with information available on germline PALB2 pathogenic variant status. Reported histological subtypes included serous adenocarcinoma (74.8%), endometroid (6.5%), clear cell (2.1%), mucinous (3.1%), and other (13.5%). Most ovarian cancers were stages III (73.5%) and IV (22.3%), followed by II (6.0%), and I (4.1%). Among ovarian cancer cases with PALB2 sequencing data available, 0.4% demonstrated a germline pathogenic variant in the PALB2 gene and the pooled odds ratio (OR) for having a PALB2 mutation was 2.31 (95% CI 0.89- 5.98). Among 94 patients with a germline PALB2 pathogenic variant, the pooled odds ratio (OR) for developing ovarian cancer was 2.85 (95% CI 1.58-5.15) relative to 33,855 patients without PALB2 mutations. Conclusions: Our meta-analysis demonstrates that the pooled OR for developing ovarian cancer with an underlying PALB2 germline pathogenic variant was 2.85 (95% CI 1.58-5.15). While this risk is lower than many of the well-established hereditary ovarian cancer genes, it does exceed the baseline population risk of 1-2%. Whether this meets the threshold to consider risk-reducing salpingo-oophorectomy is up for debate. Large population-based studies and evaluation of the combination of PALB2 mutations and cancer family history are needed to improve management recommendations for patients harboring pathogenic mutations in this gene.
- Published
- 2022
41. Relative disclosure of information on hereditary cancer syndromes: A systematic review and meta-analysis
- Author
-
Muhammad Danyal Ahsan, Hannah Bergeron, Jenny Lin, Priyanka Narayan, Becky Baltich Nelson, Xuan Li, Charlene Thomas, Paul J. Christos, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Ravi Sharaf, and Melissa Kristen Frey
- Subjects
Cancer Research ,Oncology - Abstract
10592 Background: Evidence-based guidelines recommend that patients (probands) diagnosed with a hereditary cancer syndrome share the information with blood relatives as relatives can have 50% risk for harboring the same pathogenic mutation. This information offers the opportunity for relatives to undergo genetic counseling, genetic testing, early detection, and prevention of cancer. Limited literature on this topic suggests underutilization of recommended family member disclosure. We sought to evaluate rates of familial disclosure of hereditary cancer syndrome information in the first meta-analysis on this topic. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO no.: CRD42020134276). We searched key electronic databases to identify studies evaluating hereditary cancer cascade relative disclosure. Eligible trials were subjected to meta-analysis. Results: Thirty studies met inclusion criteria. This review included 3,779 probands and 12,751 at-risk relatives. Among 12,751 included relatives, 72% (CI 64-79%) received information about the hereditary cancer syndrome identified in their family and 28% (CI 19-37%) underwent genetic testing. On meta-analysis, there was a higher rate of disclosure among female vs male relatives (79% [73% - 84%] vs 67% [57% - 75%]) and a higher rate among first-degree vs. second degree relatives (83% [77% - 88%] vs 58% [45 – 69%]). The data regarding the contribution of race/ethnicity to disclosure were limited and inconsistent, with two studies demonstrating non-White vs. White relatives being less likely to have results disclosure and two studies finding no correlation; however, both studies finding no difference were limited by small sample sizes. Finally, one study found that higher proband annual income was associated with improved familial disclosure. Conclusions: Despite a growing understanding of the importance of cascade genetic counseling and testing, probands do not disclosure information on hereditary cancer syndromes to most at-risk relatives. Very few relatives complete genetic testing, representing a critical missed opportunity for precision cancer prevention. Future studies are needed to elucidate barriers to hereditary cancer syndrome disclosure and create innovative strategies to facilitate this essential process.
- Published
- 2022
42. The Psychological Impact of COVID-19 on Medical Students Interested in Obstetrics and Gynecology [A57]
- Author
-
Jenny Lin, Briana Christophers, Edwin Nieblas-Bedolla, Janna S. Gordon-Elliott, Kevin Holcomb, and Melissa K. Frey
- Subjects
Obstetrics and Gynecology - Published
- 2022
43. Recommendations for the content and management of Certificates of Analysis for reference standards from the GCC for bioanalysis
- Author
-
Stacie McCown, Dave Williams, Esme Farley, Jennifer Zimmer, Mark O'Dell, Roger Hayes, Joseph Bower, Ashley Brant, Colin Barry, Todd Lester, Shane Karnik, Elizabeth Groeber, Wei Garofolo, Jennifer Vance, Edward Tabler, Amanda Hays, Dawn Dufield, Marsha Luna, Mitesh Sanghvi, Kurt J. Sales, Rachel Sun, Kelly Dong, Jenny Lin, Anahita Keyhani, Xinping Fang, Orlando Bravo, Natasha Savoie, Steve Lowes, Daksha Desai-Krieger, Allan Xu, Chris Beaver, Cheikh Kane, Sumit Kar, Heidi Renfrew, Christina Satterwhite, Brian K. Hoffpauir, Fabio Garofolo, Sarah Simchik, Stephanie Cape, and Rafiq Islam
- Subjects
Bioanalysis ,010401 analytical chemistry ,Clinical Biochemistry ,Library science ,General Medicine ,Reference Standards ,030226 pharmacology & pharmacy ,01 natural sciences ,Antibodies ,0104 chemical sciences ,Analytical Chemistry ,03 medical and health sciences ,Medical Laboratory Technology ,0302 clinical medicine ,Humans ,Biological Assay ,Business ,General Pharmacology, Toxicology and Pharmaceutics ,Reference standards - Abstract
The 13th Global CRO Council (GCC) closed forum for bioanalysis was held in New Orleans, LA, USA on 5 April 2019. This GCC meeting was organized to discuss the contents of the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline published in February 2019 and consolidate the feedback of the GCC members. While ICH M10 will cover requirements for reference standards, one of the biggest challenges facing the CRO community is the lack of consistency and completeness of Certificates of Analysis for reference standards used in regulated bioanalysis. Similar challenges exist with critical reagents (e.g., capture and detection antibodies) used for assays supporting biologics. The recommendations provided in this publication are the minimum requirements for the content that GCC members believe should be included in Certificates of Analysis for reference standards obtained from commercial vendors, sponsors and compendial suppliers, for use in regulated bioanalytical studies. In addition, recommendations for internal standards, metabolites and critical reagents are discussed.
- Published
- 2021
44. A systematic review and meta-analysis of genetic assessment for women with ovarian cancer: how can we do better?
- Author
-
Paul J. Christos, Rachel Saganty, Andrea Khoury, Eloise Chapman-Davis, Julia Feit, Evelyn Cantillo, Ravi Sharaf, Jenny Lin, Charlene Thomas, Melissa K. Frey, Zhen Ni Zhou, Drew Wright, and Kevin Holcomb
- Subjects
medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,Referral ,business.industry ,Genetic counseling ,Population ,Obstetrics and Gynecology ,Cochrane Library ,medicine.disease ,Confidence interval ,Oncology ,Internal medicine ,Meta-analysis ,medicine ,business ,education ,Ovarian cancer ,Genetic testing - Abstract
Objectives: Despite clear consensus guidelines recommending universal germline genetic testing in ovarian cancer patients and a growing appreciation of the significant health implications for patients and their relatives, fewer than 50% of women with ovarian cancer undergo genetic testing. We aim to use systematic review and meta-analysis to assess the status of genetic testing in ovarian cancer and identify strategies that can improve uptake of genetic assessment in this high-risk population. Methods: A complete systematic search of online databases (PubMed, EMBASE, MEDLINE, and the Cochrane Library) for studies reporting on genetic testing in ovarian cancer without date restriction was performed. Random effects pooled proportions were calculated using the logit transformation and 95% confidence intervals for individual study proportions were calculated using the Clopper-Pearson exact method. Results: The comprehensive search produced 3026 studies, among which 38 met inclusion criteria. Among studies listing mean age of diagnosis, stage, and histology data, the median of the mean age of diagnoses across the studies was 60.5 years. The median proportion of patients with early stage (I/II) ovarian cancer was 22.8%, late stage (III/IV) 70%, and unknown stage 3.6%. The median proportion of patients with serous histology was 74.6%, endometrioid 8.6%, mucinous 6%, clear cell 7%, mixed 3.6%, carcinosarcoma 3.4%, adenocarcinoma 5.8%, and other/unknown histology 7.9%. Twenty-one papers described rates of referral to genetic counseling and found, among 9,629 women, a referral rate of 56% [CI 32-78%]. Twenty-three papers described genetic testing uptake without a specified intervention and found, among 16,412 women, 34% [CI 23-47%] underwent genetic testing (Figure 1). For patients completing genetic testing, 27% [CI 22-32%] had a pathogenic mutation and 7% [CI 3-16%] a variant of uncertain significance. The most successful strategy aimed at improving rates of genetic testing was ‘mainstreaming,’ the process of providing counseling and testing in the oncology clinic by trained non-genetics specialists. With mainstreaming, 99% [CI 86-100%] of patients completed genetic testing. Other strategies described in the literature included the use of telemedicine for genetic services (75% underwent genetic testing [CI 43-93%]), embedding a genetic counselor in the clinic (67% [CI 32-90%]), reflex somatic tumor BRCA1/2 testing to triage to germline testing (64% [17-94%]), practice recommendation for universal testing of all ovarian cancer patients (42% [CI 15-74%]), and incorporating dedicated referral forms into practice (26% [CI 10-53%]). Download : Download high-res image (203KB) Download : Download full-size image Conclusions: Identifying causative germline mutations in ovarian cancer can impact treatment decisions, inform risk of other malignancies and guide disease prevention and early detection in at-risk relatives. Rates of both referral to genetic counseling and testing remain low, 56% and 34% respectively, despite broad recommendations for universal testing. Mainstreaming, use of telemedicine, embedding genetic counselors in the clinic, and triage via reflex somatic BRCA1/2 assessment are all strategies demonstrating success in this patient population and should be considered for those providing care to women with ovarian cancer.
- Published
- 2021
45. Disparities in genetic testing for women with ovarian cancer: a systematic review
- Author
-
Andrea Khoury, Rachel Saganty, Paul J. Christos, Julia Feit, Ravi Sharaf, Drew Wright, Melissa K. Frey, Charlene Thomas, and Jenny Lin
- Subjects
medicine.medical_specialty ,Referral ,medicine.diagnostic_test ,business.industry ,Genetic counseling ,MEDLINE ,Obstetrics and Gynecology ,Cochrane Library ,Confidence interval ,Study heterogeneity ,Oncology ,Internal medicine ,medicine ,business ,Medicaid ,Genetic testing - Abstract
Objectives: Despite the recommendation for genetic assessment for all women with ovarian cancer, the limited available data suggest significant disparities in referral and uptake of genetic services in minority populations. Additionally, the COVID-19 pandemic has exacerbated many existing health care disparities, making it even more critical that inequalities be identified and addressed. We sought to evaluate differences in genetic counseling and genetic testing among women with ovarian cancer based on race and insurance status. Methods: A complete systematic search of online databases (PubMed, EMBASE, MEDLINE, and the Cochrane Library) for studies reporting on genetic testing in ovarian cancer without date restriction was performed. Random effects pooled proportions were calculated using the logit transformation and 95% confidence intervals for individual study proportions were calculated using the Clopper-Pearson exact method. Results: The comprehensive search produced 3026 studies, among which 38 met inclusion criteria. Eight studies included analysis by self-reported race/ethnicity and 6 included analysis by insurance status. Among studies listing mean age of diagnosis, stage, and histology data, the median of the mean age of diagnoses across the studies was 63.3 years. The median proportion of patients with early stage (I/II) ovarian cancer was 14.7%, late stage (III/IV) 68.6%, and unknown stage 9.3%. The median proportion of patients with serous histology was 81.8%, endometrioid 12.6%, mucinous 5%, clear cell 5.8%, mixed 3.7%, carcinosarcoma 3%, and other/unknown histology 81.8%. Among 7,862 patients, 6,469 reported being White, 599 Black, and 794 Asian. Random-effects pooled proportions by race/ethnicity to follow: Among White patients, 43% [CI 26-62%] were referred for genetic counseling and 40% [CI 25-57%] completed testing, and for Black patients, 24% [CI 13-42%] were referred for counseling and 26% [CI 17-38%] completed testing. For Asian patients, 23% [CI 2-83%] were referred for counseling and 14% [CI 2-51%] completed testing, although only two studies included referral and testing proportions in Asian patients, with the majority of patient data coming from one study with referral proportion of 39% and another study with testing proportion of 31%. Among 7,681 patients, 5,320 (69%) had private insurance, 2,078 (27%) had Medicare/Medicaid, and 283 (4%) were uninsured. Random-effects pooled proportions by insurance status to follow: Among patients with private insurance, 39% [CI 26-54%] were referred for genetic counseling and 47% [CI 30-64%] completed testing. Among patients with Medicare/Medicaid, 27% [CI 18-38%] were referred for counseling and 26% [CI 16-40%] completed testing, and among uninsured patients, 24% [CI 13-41%] were referred for counseling and 23% [CI 18-28%] completed testing. Small sample and high study heterogeneity observed in the race and insurance data resulted in large confidence intervals in the pooled proportions of interest. Conclusions: Rates of genetic counseling and genetic testing are below national guidelines for all women with ovarian cancer. Our systematic review of the existing literature on this topic suggests that minority women and patients without private insurance may be disproportionally affected by lower referral rates and more limited access to genetic testing. This disparity is concerning as it can have significant impact on the health of the affected patient and her at-risk relatives. Download : Download high-res image (212KB) Download : Download full-size image
- Published
- 2021
46. Family health history of gynecologic oncology patients: can we do better?
- Author
-
Paul J. Christos, Andreas Lackner, Charlene Thomas, Charlotte Gamble, Evelyn Cantillo, Ryan Kahn, Steven M. Lipkin, Kevin Holcomb, Hannah Krinsky, Eloise Chapman-Davis, Jenny Lin, Ravi Sharaf, and Melissa K. Frey
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Medical record ,Obstetrics and Gynecology ,Cancer ,Retrospective cohort study ,Gynecologic oncology ,medicine.disease ,Oncology ,Family medicine ,Pandemic ,medicine ,Family history ,business ,Cause of death ,Genetic testing - Abstract
Objectives: Despite a growing understanding of familial cancer, multiple studies demonstrate that the quality of family health history (FHH) as currently collected in a clinic setting is inadequate to assess disease risk. Proposed challenges in FHH collection include lack of patient preparation, lack of FHH standardization, and time requirement (especially during the COVID-19 pandemic with intentional minimization of office time). Prior to implementation of a web-based application for FHH collection, we aimed to review the quality of collected FHH in a gynecologic oncology clinic and to determine if any patient factors affect FHH collection. Methods: This was a single institution retrospective study of FHH collection for new patient appointments at a gynecologic oncology outpatient practice between 4/2019-7/2019. FHH was collected verbally during the patient face-to-face interview. FHH was evaluated for the following, previously published, quality measures on a point system: 1) Three generations, 2) Relative gender, 3) Relative lineage (maternal vs paternal), 4) Pertinent negatives (absence of hereditary cancers), 5) Age of relatives’ cancer diagnosis, and for deceased relatives, 6) Age of death and 7) Cause of death. Results: Among the 200 evaluable patients, 185 (92.5%) had FHH documented in the medical record. The median age was 52 years (range 23-93). Eighty-nine (44.5%) included three generations, 154 (77%) relatives’ gender, 109 (54.5%) relatives’ lineage, and 77 (38.5%) pertinent negatives (Figure 1). Among 147 patients reporting a history of cancer in their family, 23 (15.6%) included age of relatives’ cancer diagnosis. Among 75 patients listing deceased relatives, 13 (17.3%) included age of death and 48 (64%) cause of death. Age and personal cancer diagnosis were not associated with quality of FHH. Patients with family history of cancer scored higher in quality of FHH than those without family history (median=3.0 [IQR 3.0; 4.0] vs. 1.0 [0.0; 2.0], P Download : Download high-res image (82KB) Download : Download full-size image Conclusions: Our data are consistent with the literature suggesting that standard collection of family history may not adequately capture all measures of a high quality oncologic FHH. Patients without prior genetic testing and no family history of cancer had the lowest scores for FHH quality and might benefit from a web-based FHH collection tool, allowing them to contact relatives for more information prior to an office visit and permitting better patient preparation and efficiency. In light of the COVID-19 pandemic, tools that minimize inoffice time are increasingly important. A prospective evaluation of a web-based FHH collection tool to address these issues is ongoing.
- Published
- 2021
47. Using health information technology to improve collection of family cancer history: prospective randomized trial of web-based tool in a gynecologic oncology outpatient clinic
- Author
-
Noelani Wing, Jenny Lin, Karen Bolouvi, Melissa K. Frey, Sunidhi Singh, Evelyn Cantillo, Paul J. Christos, Muhammad Danyal Ahsan, Eloise Chapman-Davis, Hannah Krinsky, Daniel Litvin, Ravi Sharaf, Kevin Holcomb, Corbyn Nchako, and Charlene Thomas
- Subjects
medicine.medical_specialty ,Cancer prevention ,Family Cancer History ,business.industry ,Obstetrics and Gynecology ,Gynecologic oncology ,Triage ,law.invention ,Oncology ,Randomized controlled trial ,law ,Cohort ,Clinical endpoint ,Physical therapy ,Medicine ,Outpatient clinic ,business - Abstract
Objectives: In the US there are approximately 4 million individuals with a genetic cancer predisposition syndrome, however, the majority are not aware and cannot benefit from genetically-targeted cancer prevention. Family cancer history (FCH) can identify high risk patients and triage them to genetic assessment, however there is wide variability in accuracy, breadth and strategies for FCH collection. We aim to evaluate whether a web-based tool (WBT) can result in improved quality of FCH versus standard FCH collection via face-to-face interview. Methods: All patients scheduled for a gynecologic oncology new patient visit between 9/2019-9/2020 were offered enrollment in an institutional review board-approved prospective trial. Patients were randomized to one of three arms: 1) standard of care FCH collection during the interview, 2) WBT administered at home prior to the visit, 3) WBT administered in the office prior to the visit. The primary endpoint was evaluation of FCH quality based on established quality measures. Chi-square test was used to compare FCH quality between intervention arms and ANOVA test for the number of relatives/generations in the pedigree. A Bonferroni correction was used to account for multiple comparison testing. Results: A total of 100 patients were enrolled. The mean age was 56.2 years (SD 15.2). The WBT was completed successfully by 67% (22) of patients randomized to home administration vs 94% (31) randomized to office administration (P=0.01). Patients cited the following reasons for failure to complete the WBT at home: difficulty with technology, concern about privacy and forgetting about the WBT invitation. In the intention-to-treat analysis, office WBT collection resulted in significantly higher quality FCH vs the control and home arms (Table 1). The WBT resulted in significantly greater mean number of relatives included in the pedigree (Arm 1 - 3.9 [SD 3.0], Arm 2 - 32.4 [SD 16.8], Arm 3 - 29.0 [SD 18.3], P Download : Download high-res image (102KB) Download : Download full-size image Conclusions: FCH collection is an exciting application of information technology in the current healthcare setting with a growing emphasis on cancer genetics, disease prevention and thoughtful use of WBTs. In our cohort of gynecologic-oncology patients, a WBT resulted in significantly higher quality and more comprehensive family cancer pedigrees. With the COVID-19 pandemic inspired drive to minimize in-office time, future studies must assess strategies to improve patient engagement with WBT at home prior to the visit.
- Published
- 2021
48. Silicon Wafers and Office Park Dreams : Cross-Cultural Designs, Aesthetics, and Art in and around California’s Santa Clara Valley
- Author
-
Jenny Lin
- Subjects
media_common.quotation_subject ,Cross-cultural ,Art ,Archaeology ,media_common - Abstract
This chapter examines the visual culture of Silicon Valley. I look to Silicon Valley’s “golden years,” exemplified by the establishment of Xerox PARC in the 1970s, and analyse how PARC’s researchers’ embrace of open exchange and experimentation manifested in university campus-like office design. I subsequently consider the morphing of PARC’s design into the monumental corporate architecture of Apple Park, and the work/ play environments of Google and Airbnb. I argue that these late capitalist corporations aestheticize Silicon Valley’s foundational values, transforming the promotion of cross-cultural sharing into empty visual signs that mask economic inequality and displacement. Finally, the chapter discusses collaborations between artists and community groups, facilitated by the San José Museum of Art, which aim to reclaim multiculturalism and resist the area’s unsustainable gentrification.
- Published
- 2021
49. Aesthetics of Gentrification
- Author
-
Christoph Lindner, Gerard Sandoval, Susanna Newbury, Daan Wesselman, Nate Storring, Guillaume Sirois, Gillian Jein, Samuel Zipp, Rebecca Amato, Brandi Summers, Jenny Lin, Jennifer Hock, Jan Lin, Beatriz Kalichman, Beatriz Rufino, Jonathan Jae-an Crisman, and Ayona Datta
- Abstract
Gentrification is reshaping cities worldwide, resulting in seductive spaces and exclusive communities that aspire to innovation, creativity, sustainability, and technological sophistication. Gentrification is also contributing to growing social-spatial division and urban inequality and precarity. In a time of escalating housing crisis, unaffordable cities, and racial tension, scholars speak of eco-gentrification, techno-gentrification, super-gentrification, and planetary gentrification to describe the different forms and scales of involuntary displacement occurring in vulnerable communities in response to current patterns of development and the hype-driven discourses of the creative city, smart city, millennial city, and sustainable city. In this context, how do contemporary creative practices in art, architecture, and related fields help to produce or resist gentrification? What does gentrification look and feel like in specific sites and communities around the globe, and how is that appearance or feeling implicated in promoting stylized renewal to a privileged public? In what ways do the aesthetics of gentrification express contested conditions of migration and mobility? Addressing these questions, this book examines the relationship between aesthetics and gentrification in contemporary cities from multiple, comparative, global, and transnational perspectives.
- Published
- 2021
50. Representing Crochet with Stitch Meshes
- Author
-
Jenny Lin, James McCann, Vidya Narayanan, and Michelle Guo
- Subjects
Loop (graph theory) ,Parsing ,Hook ,Computer science ,Yarn ,computer.software_genre ,Notation ,Set (abstract data type) ,Face (geometry) ,visual_art ,Computer graphics (images) ,visual_art.visual_art_medium ,Polygon mesh ,computer ,ComputingMethodologies_COMPUTERGRAPHICS - Abstract
Crochet is a fabrication technique in which a 3D surface is created from yarn by interlacing loops formed with a special hook. Crochet patterns are typically represented using a standardized set of abstract pictorial symbols. Unfortunately, while this notation is enough for someone well-versed in the individual stitches, it does not directly show the yarn layout of stitches. This lack of specification makes it difficult for both novice users and computer programs to parse, visualize, and design crochet patterns. We demonstrate how to represent crochet patterns within the “stitch mesh” paradigm. That is, the pattern is represented using a library of tiles, where each tile contains yarn geometry, and tiles connect along their edges. In order to adapt stitch meshes to crochet, we introduce a special edge type which captures the idea of the current loop – the loop of yarn held on the crochet hook during fabrication. We also create a library of mesh face types which model commonly-used crochet stitches. We illustrate the richness of the crochet stitch faces by showing a number of examples including patterns generated from 3D models.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.